Patients who have relapsed or failed first-line treatment for aggressive forms of B-cell non-Hodgkin lymphoma may qualify to receive a promising CAR T-cell therapy in a new Phase II clinical trial at Providence Cancer Institute:
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
JCAR017 is an investigational CAR T-cell therapy in which a patient’s own T cells are engineered to express a chimeric antigen receptor (CAR) targeting the CD19 antigen – a protein expressed on the surfaces of normal and malignant B cells. Like other T cells, CAR T cells are also endowed with an immune activating receptor. It is this dual-purpose function of antigen targeting and immune activation that gives CAR T cells their anti-cancer potency.
Whereas CAR T-cell therapy had been limited to inpatient treatment at university medical centers, patients who quality for the study can now receive therapy in the outpatient setting.
A Phase I study of JCAR017 in patients with aggressive forms of B-cell lymphoma found that it provided “a durable reduction or eradication of cancer,” including complete cancer eradication in just over half of the patients. Read more in Lymphoma News Today.
CAR T-cell therapy is a major research priority for the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center. Read more about JCAR017 in Immuno-Oncology News, and find out more about adoptive T-cell therapy research at Providence.
Providence Cancer Institute is one of 13 centers in the United States currently participating in this study. For more information or to enroll a patient, call our Clinical Research office at 503-215-2614 or submit a referral form. Contact us early for consideration, before the patient receives a salvage therapy or stem cell transplant.
See more studies
New research studies are added frequently. See all studies in all cancer types currently open at Providence Cancer Institute.